These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 12951819)

  • 1. Antisense and RNAi: powerful tools in drug target discovery and validation.
    Lavery KS; King TH
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):561-9. PubMed ID: 12951819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tools for target identification and validation.
    Wang S; Sim TB; Kim YS; Chang YT
    Curr Opin Chem Biol; 2004 Aug; 8(4):371-7. PubMed ID: 15288246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-target identification in Drosophila cells: combining high-throughout RNAi and small-molecule screens.
    Perrimon N; Friedman A; Mathey-Prevot B; Eggert US
    Drug Discov Today; 2007 Jan; 12(1-2):28-33. PubMed ID: 17198970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense and RNA interference approaches to target validation in pain research.
    Kurreck J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):179-87. PubMed ID: 15603251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The multiple orthogonal tools approach to define molecular causation in the validation of druggable targets.
    Hardy LW; Peet NP
    Drug Discov Today; 2004 Feb; 9(3):117-26. PubMed ID: 14960389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNAi and high-content screening in target identification and validation.
    Haney SA
    IDrugs; 2005 Dec; 8(12):997-1001. PubMed ID: 16320133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA interference screening for the discovery of oncology targets.
    Quon K; Kassner PD
    Expert Opin Ther Targets; 2009 Sep; 13(9):1027-35. PubMed ID: 19650760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Commercial potential of RNAi.
    Jain KK
    Mol Biosyst; 2006 Nov; 2(11):523-6. PubMed ID: 17216033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal antisense therapy: preclinical models with a clinical future?
    Bitko V; Barik S
    Curr Opin Mol Ther; 2007 Apr; 9(2):119-25. PubMed ID: 17458164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNAi: a novel antisense technology and its therapeutic potential.
    Dallas A; Vlassov AV
    Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biology calls the targets: combining RNAi and disease biology.
    van Es HH; Arts GJ
    Drug Discov Today; 2005 Oct; 10(20):1385-91. PubMed ID: 16253877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of antisense oligonucleotides for gene functionalization and target validation.
    Bennett CF; Cowsert LM
    Curr Opin Mol Ther; 1999 Jun; 1(3):359-71. PubMed ID: 11713801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo target validation using gene invalidation, RNA interference and protein functional knockout models: it is the time to combine.
    Vidalin O; Muslmani M; Estienne C; Echchakir H; Abina AM
    Curr Opin Pharmacol; 2009 Oct; 9(5):669-76. PubMed ID: 19646923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. siRNAs in drug discovery: target validation and beyond.
    Natt F
    Curr Opin Mol Ther; 2007 Jun; 9(3):242-7. PubMed ID: 17608022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA-mediated gene silencing: mechanisms and its therapeutic applications.
    Verma NK; Dey CS
    J Clin Pharm Ther; 2004 Oct; 29(5):395-404. PubMed ID: 15482382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using RNAi in the clinic.
    Dev KK
    IDrugs; 2006 Apr; 9(4):279-82. PubMed ID: 16596482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How will RNAi facilitate drug development?
    Bartz S; Jackson AL
    Sci STKE; 2005 Aug; 2005(295):pe39. PubMed ID: 16077085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From genome to phenome--RNAi library screening and hit characterization using signaling pathway analysis.
    Chatterjee-Kishore M
    Curr Opin Drug Discov Devel; 2006 Mar; 9(2):231-9. PubMed ID: 16566293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the sounds of silence: RNAi-mediated gene silencing for target identification and validation.
    Chatterjee-Kishore M; Miller CP
    Drug Discov Today; 2005 Nov; 10(22):1559-65. PubMed ID: 16257379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.